009300.KQ
Sam-A Pharm. Co., Ltd
KOSDAQKRWEQUITY
DELAYED
Last price
13,690.00
▲ 20.00 (0.15%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13,670.00
Prev close
13,670.00
Day high
0.00
Day low
0.00
Volume
0
Market cap
$83.55B
P/E (TTM)
—
52W range
0.00 – 17,480.00
Day trading desk
Gap from prior close
0.00%
Prior close 13,670.00
VWAP
13,637.81
+0.38% from price
Relative volume
0.75×
Normal
Session range
2.61%
13,420.00 – 13,770.00
Position in range
77%
Near session high
ATR (14D)
377.86
2.76% of price
Prior day high
13,760.00
PDH
Prior day low
13,480.00
PDL
Bid / ask spread
—
Quote not published
Session volume
4.43K
Avg 5.88K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.41%
+2.8%
1M
+12.12%
+8.4%
3M
-12.30%
-15.4%
6M
-15.13%
-26.2%
YTD
-12.86%
-25.1%
1Y
-24.57%
-44.6%
3Y
-20.13%
-94.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on 009300.KQ open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap$83.55B
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $77.80B | $95.58B | $97.21B | $81.70B | -18.6% |
| Operating revenue | $77.80B | $95.58B | $97.21B | $81.70B | -18.6% |
| Cost of revenue | $31.44B | $34.75B | $35.59B | $31.54B | -9.5% |
| Gross profit | $46.36B | $60.83B | $61.62B | $50.16B | -23.8% |
| Research & development | $6.14B | $5.42B | $6.40B | $3.77B | +13.2% |
| Selling, general & admin | $11.36B | $12.26B | $12.11B | $11.11B | -7.3% |
| Total operating expense | $35.38B | $36.36B | $38.12B | $31.91B | -2.7% |
| Operating income | $10.98B | $24.47B | $23.50B | $18.25B | -55.1% |
| Net interest income | $4.45B | $4.93B | $4.42B | $2.37B | -9.8% |
| Pre-tax income | $16.03B | $29.27B | $28.48B | $18.40B | -45.2% |
| Tax provision | $3.09B | $7.19B | $7.10B | $6.49B | -57.0% |
| Net income | $12.94B | $22.08B | $21.37B | $11.91B | -41.4% |
| Net income to common | $12.94B | $22.08B | $21.37B | $11.91B | -41.4% |
| Basic EPS | 2,120.00 | 3,618.00 | 3,502.00 | 1,952.00 | -41.4% |
| Diluted EPS | 2,120.00 | 3,618.00 | 3,502.00 | 1,952.00 | -41.4% |
| EBIT | $16.47B | $29.81B | $28.70B | $18.46B | -44.7% |
| EBITDA | $21.28B | $34.07B | $32.59B | $21.65B | -37.5% |
| Basic shares | 6.10M | 6.10M | 6.10M | 6.10M | +0.0% |
| Diluted shares | 6.10M | 6.10M | 6.10M | 6.10M | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.58B | $9.55B | $9.02B | $9.18B | — | -31.1% |
| Cash & short-term investments | $97.64B | $76.66B | $79.10B | $81.01B | — | +27.4% |
| Accounts receivable | $19.47B | $19.06B | $22.60B | $21.47B | — | +2.1% |
| Inventory | $16.47B | $14.28B | $13.01B | $12.24B | — | +15.3% |
| Total current assets | $135.87B | $113.09B | $117.99B | $116.86B | — | +20.1% |
| Property, plant & equipment | $39.17B | $42.75B | $40.51B | $37.16B | — | -8.4% |
| Goodwill & intangibles | $4.64B | $4.19B | $4.30B | $4.39B | — | +10.8% |
| Total assets | $247.04B | $248.73B | $231.31B | $203.20B | — | -0.7% |
| Total current liabilities | $13.89B | $20.51B | $21.14B | $21.56B | — | -32.3% |
| Current debt | $2.28B | $4.56B | $1.67B | — | $2.41B | -50.0% |
| Long-term debt | — | $2.28B | $2.50B | — | — | — |
| Total debt | $6.94B | $12.89B | $11.67B | $1.77B | — | -46.1% |
| Total liabilities | $18.93B | $28.76B | $30.84B | $22.58B | — | -34.2% |
| Retained earnings | $204.17B | $196.48B | $179.20B | $160.35B | — | +3.9% |
| Shareholder equity | $228.11B | $219.98B | $200.47B | $180.62B | — | +3.7% |
| Working capital | $121.98B | $92.58B | $96.85B | $95.30B | — | +31.8% |
| Net tangible assets | $223.47B | $215.79B | $196.17B | $176.22B | — | +3.6% |
| Shares issued | 6.10M | 6.37M | 6.37M | 6.37M | — | -4.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $12.94B | $22.08B | $21.37B | $11.91B | -41.4% |
| Depreciation & amortisation | $4.81B | $4.27B | $3.90B | $3.19B | +12.7% |
| Change in working capital | -$3.07B | -$1.66B | -$3.33B | -$403.53M | -84.8% |
| Operating cash flow | $10.72B | $25.25B | $20.76B | $19.60B | -57.5% |
| Capital expenditure | -$1.78B | -$6.51B | -$3.82B | -$239.25M | +72.7% |
| Investing cash flow | -$2.56B | -$21.41B | -$20.81B | -$13.03B | +88.0% |
| Dividends paid | -$4.88B | -$4.58B | -$2.44B | -$1.53B | -6.7% |
| Financing cash flow | -$11.13B | -$3.52B | -$111.77M | -$5.38B | -216.0% |
| Free cash flow | $8.94B | $18.74B | $16.94B | $19.37B | -52.3% |
| End cash position | $6.58B | $9.55B | $9.02B | $9.18B | -31.1% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $17.63B | $20.76B | $15.11B | $17.42B | $24.50B | — | -15.1% |
| Operating revenue | $17.63B | $20.76B | $15.11B | $17.42B | $24.50B | — | -15.1% |
| Cost of revenue | $7.45B | $9.20B | $6.76B | $7.00B | $8.48B | — | -19.1% |
| Gross profit | $10.18B | $11.56B | $8.36B | $10.42B | $16.02B | — | -11.9% |
| Research & development | $1.71B | $1.52B | — | — | $979.46M | $1.88B | +12.9% |
| Selling, general & admin | $2.36B | $2.75B | $9.48B | $8.41B | $3.00B | — | -14.0% |
| Total operating expense | $8.10B | $8.91B | $9.48B | $8.41B | $8.58B | — | -9.1% |
| Operating income | $2.08B | $2.65B | -$1.12B | $2.01B | $7.44B | — | -21.5% |
| Net interest income | $1.00B | $1.06B | $1.08B | $1.10B | $1.21B | — | -5.4% |
| Pre-tax income | $2.98B | $4.27B | -$26.47M | $3.27B | $8.51B | — | -30.3% |
| Tax provision | $748.97M | $256.69M | $27.59M | $581.36M | $2.23B | — | +191.8% |
| Net income | $2.23B | $4.02B | -$54.06M | $2.69B | $6.28B | — | -44.5% |
| Net income to common | $2.23B | $4.02B | -$54.06M | $2.69B | $6.28B | — | -44.5% |
| Basic EPS | 365.00 | — | -9.00 | 441.00 | 1,029.00 | — | — |
| Diluted EPS | 365.00 | — | -9.00 | 441.00 | 1,029.00 | — | — |
| EBIT | $2.08B | $8.15B | -$1.12B | $2.01B | $7.44B | — | -74.4% |
| EBITDA | $2.66B | $9.38B | $96.62M | $3.21B | $8.60B | — | -71.6% |
| Basic shares | 6.10M | — | 6.10M | — | 6.11M | — | — |
| Diluted shares | 6.10M | — | 6.10M | 6.10M | 6.11M | — | — |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14.67B | $6.58B | $6.32B | $9.39B | $16.26B | — | +123.0% |
| Cash & short-term investments | $102.19B | $97.64B | $90.90B | $88.31B | $84.46B | — | +4.7% |
| Accounts receivable | $17.29B | $19.47B | $15.13B | $16.49B | $20.16B | — | -11.2% |
| Inventory | $15.33B | $16.47B | $18.14B | $17.88B | $16.38B | — | -6.9% |
| Total current assets | $137.92B | $135.87B | $127.06B | $125.26B | $123.81B | — | +1.5% |
| Property, plant & equipment | $38.25B | $39.17B | $39.79B | $40.64B | $41.98B | — | -2.4% |
| Goodwill & intangibles | $4.66B | $4.64B | $4.69B | $4.77B | $4.16B | — | +0.4% |
| Total assets | $248.12B | $247.04B | $246.13B | $248.82B | $256.05B | — | +0.4% |
| Total current liabilities | $17.70B | $13.89B | $16.32B | $19.24B | $27.76B | — | +27.5% |
| Current debt | $1.14B | $2.28B | $3.42B | $4.56B | $4.56B | — | -50.0% |
| Long-term debt | — | — | — | — | $1.14B | $2.28B | — |
| Total debt | $5.41B | $6.94B | $8.41B | $9.91B | $11.40B | — | -22.1% |
| Total liabilities | $22.22B | $18.93B | $21.72B | $24.83B | $34.64B | — | +17.4% |
| Retained earnings | $201.21B | $204.17B | $200.52B | $200.58B | $197.88B | — | -1.4% |
| Shareholder equity | $225.89B | $228.11B | $224.41B | $223.99B | $221.41B | — | -1.0% |
| Working capital | $120.22B | $121.98B | $110.74B | $106.02B | $96.06B | — | -1.4% |
| Net tangible assets | $221.23B | $223.47B | $219.72B | $219.22B | $217.25B | — | -1.0% |
| Shares issued | 6.37M | 6.10M | 6.37M | 6.37M | 6.37M | — | +4.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $2.23B | $4.02B | -$54.06M | $2.69B | $6.28B | — | -44.5% |
| Depreciation & amortisation | $542.91M | $1.23B | $1.22B | $1.20B | $1.16B | — | -55.8% |
| Change in working capital | $2.41B | -$3.54B | $1.30B | $232.94M | -$1.06B | — | +168.0% |
| Operating cash flow | $6.62B | $162.42M | $719.70M | — | $7.62B | $1.06B | +3,973.5% |
| Capital expenditure | -$344.43M | -$687.24M | -$389.25M | -$681.29M | -$20.76M | — | +49.9% |
| Investing cash flow | $3.03B | $1.66B | -$2.23B | -$2.64B | $645.26M | — | +82.8% |
| Dividends paid | — | $0 | $0 | — | — | $0 | — |
| Financing cash flow | -$1.57B | -$1.57B | -$1.57B | -$6.44B | -$1.55B | — | -0.1% |
| Free cash flow | $6.27B | -$524.82M | $330.45M | $1.54B | $7.60B | — | +1,295.1% |
| End cash position | $14.67B | $6.58B | $6.32B | $9.39B | $16.26B | — | +123.0% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13,571.00
+0.88% from price
SMA 20
12,968.50
+5.56% from price
SMA 50
12,885.20
+6.25% from price
SMA 100
14,257.90
-3.98% from price
SMA 200
15,156.25
-9.67% from price
EMA 12
13,375.95
+2.35% from price
EMA 26
13,122.97
+4.32% from price
EMA 50
13,269.44
+3.17% from price
RSI (14)
63.3
Neutral
MACD (12,26,9)
252.98
Hist 102.09
ATR (14)
377.86
2.76% of price
Realised vol 30D
26.2%
Annualised
Bollinger upper
14,246.52
20, 2σ
Bollinger lower
11,690.48
20, 2σ
50 / 200 cross
Death
12,885.20 vs 15,156.25
Trend bias
Below 200
-9.67%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.08
Less volatile than market
Correlation to SPY
0.04
Largely independent
Realised vol 30D
26.2%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-33.0%
Peak to trough
Max drawdown 5Y
-66.4%
Peak to trough
ATR 14
377.86
2.76% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
Raphinha, Lopez hit braces as Barcelona trounce Elche
AFP · 15m ago
Amorim starts Serie A life with Milan win, Juve edge Frosinone
AFP · 18m ago
Lawsuit filed in Napali coast ‘doors-off’ helicopter tour crash
The Honolulu Star-Advertiser · 18m ago
Does Billionaire Bill Ackman Know Something Wall Street Doesn’t? He Invested in These 2 Stocks That Have Dropped 33% and 18% Over the Past Year
Motley Fool · 19m ago
Liquor industry struggles grow with another Chapter 7 filing
TheStreet · 21m ago
Media Advisory: Housing Announcement in Toronto
CNW Group · 24m ago
Dow Jones Futures Due With Market At Key Point; Nvidia, Tariffs, Warsh In Focus
Investor's Business Daily · 31m ago
Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Motley Fool · 34m ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.